ASH: PXD101

CuraGen Corporation and TopoTarget A/S announced today that Phase I data on PXD101, a small molecule histone deacetylase (HDAC) inhibitor for the treatment of advanced hematologic and solid cancers, were presented at the American Society of Hematology Annual Meeting. Preliminary results on 16 patients show that PXD101 is well-tolerated following intravenous administration and has demonstrated potential anti-tumor activity against multiple myeloma, non-Hodgkin's lymphoma and transformed chronic lymphocytic leukemia.

Source: www.curagen.com